FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag

Why might the Fed cut interest rates in July? How will Trump’s Iran decision impact markets? What caused Circle stock to surge recently? Why is Kroger raising its sales outlook? How is AI reshaping the tech job market? What’s behind Tesla’s upcoming robotaxi launch? How are Middle East tensions affecting oil prices?

FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag

benzinga.com/news/fda/25/06/46023093/fda-approves-gileads-game-changing-twice-yearly-shot-to-prevent-hiv-transmission-critics-slam-28k-price-

During market trading hours on Wednesday, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.’s (NASDAQ:GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg,…

This story appeared on benzinga.com, 2025-06-20 11:42:35.